Barclays raised the firm’s price target on BioCryst (BCRX) to $11 from $8 and keeps an Equal Weight rating on the shares. The company reported a beat Q1 for Orladeyo, raised 2025 revenue guidance by $50M due to a 10% increase in paid rate, and announced reaching profitability one year earlier in 2025, the analyst tells investors in a research note. The firm says initial data for BCX17725 in Netherton syndrome and avoralstat could provide upside potential.
Claim 55% Off TipRanks
- Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions
- Discover top-performing stock ideas and upgrade to a portfolio of market leaders with Smart Investor Picks
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on BCRX:
- BioCryst price target raised to $13 from $11 at RBC Capital
- BioCryst price target raised to $13 from $11 at BofA
- BioCryst’s Strong Growth Prospects: Buy Rating Backed by Orladeyo’s Success and Promising Pipeline Developments
- BioCryst Pharmaceuticals Reports Strong Q1 2025 Growth
- BioCryst Pharmaceuticals Reports Record Growth and Profitability